Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a company name.

Quanta Therapeutics Inc.

Headquarters: San Francisco, CA, United States of America
Year Founded: 2018
Status: Private

BioCentury | Sep 22, 2023
Distillery Therapeutics

Noncovalent inhibitor targeting multiple KRAS mutations in cancer

BioCentury | May 22, 2023
Deals

May 22 Quick Takes: Ironwood building GI franchise via $1B VectivBio acquisition

Plus: Krystal raises $160M PIPE and updates from Avrobio-Novartis, Avidity, BMS, Hepion, Rain, Blueprint 
BioCentury | Apr 25, 2023
Product Development

KRAS’s next chapter: hitting the target’s active form 

Investors rewarded Revolution for preclinical KRAS (ON) data at AACR23, as a wave of dual KRAS (ON/OFF) inhibitors at the meeting gear up for the clinic
BioCentury | Dec 14, 2022
Management Tracks

Quanta names Exelixis alum Faoro as CMO

Plus: Abingworth adds Joy Ghosh as managing director and Renibus hires Ramdas as SVP
BioCentury | Oct 27, 2021
Product Development

Oct. 26 Quick Takes: CD8 Treg modulating play Mozart debuts with $55M

Angion, Cortexyme post Phase III misses, plus DNA Script, Novartis, Quanta, Exciva and more
Items per page:
1 - 5 of 5
Username